The New Pharmaceutical Sciences
This article was originally published in Start Up
Now that several waves of novel discovery technologies have failed to deliver promised efficiencies, pharmaceutical sciences once dismissed as boring are attracting increasing numbers of admirers. Appreciation for the practical is easing the way not only for precedented disciplines such as drug formulation and delivery, but also for utterly new technologies that offer solutions to specific R&D problems. Start-ups today know they bear a high burden of proof. Some have been hunkering down to get evidence they hope will in time convince skeptics and increase the value of their offerings, while others are agreeing to demonstrate their worth via pilot programs. Emerging start-up models are enabled by two key factors: huge stockpiles of venture capital and an expanded audience of potential partners-namely, big biotech and specialty pharmaceutical firms that are relatively wealthy and hungry for products.
You may also be interested in...
Big Pharma's Biggest Drug Delivery Experiment: Johnson & Johnson
J&J has been Big Pharma's most aggressive experimenter with the drug-delivery and formulations world, but its two biggest transactions haven't provided the value J&J had originally hoped for.
Sinclair Pharma: How Low Risk Can You Go?
Sinclair Pharma was the only health care firm to have floated in Europe in 2003; investors liked its very low risk model: take little development risk then partner for marketing. Yet in taking the specialty model to its extreme, Sinclair's challenge will be to secure enough valuable products to keep investors interested, particularly if European markets warm up and begin to embrace a new, stronger generation of R&D focused firms.
Jumpstarting Research: Big Pharma's Out-Licensing Dilemma
At Windhover's Jumpstart to Products Conference, a number of speakers, including Merck's head of basic research, argued--at least by implication--that Big Pharma needs to do more of the kinds of reformulations and re-indications of existing compounds that net them products faster and with less risk--that allow them to "jumpstart" R&D. For biotechs pursuing a similar strategy, getting starter material--in the form of compounds Pharma has abandoned--is crucial, though few Pharmas are willing to out-license. Lilly is the great exception to this rule: the company's Joe Zakrzewski argues why outlicensing is critical to his firm's success.